

1st November 2017 | CannPal Animal Therapeutics Limited ACN: 612 791 518 |
ASX:CP1

CannPal Granted a Permit to Possess and Supply Cannabis by NSW State Department of Health

Key Highlights

- CannPal has been granted a permit to possess and supply tetrahydrocannabinol and cannabidiol for the purpose of scientific research by the NSW State Department of Health
- The permit allows the provision of cannabis to researchers in NSW for the purpose of CannPal's clinical trials in Q1 CY18
- The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985
- The permit will enable CannPal to seek permission from the Office of Drug Control and the Australian Pesticides and Veterinary Medicines Authority to import cannabis for its planned clinical trials

Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has been granted authorisation to possess and supply cannabis for scientific research by the NSW State Department of Health.

The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985 and allows CannPal to apply for Australian Pesticides and Veterinary Medicines Authority (APVMA) and Office of Drug Control (ODC) permits to import cannabis for the commencement of the Company's clinical trials planned for Q1 CY18.

CannPal has been working closely with Invetus Limited ("Invetus"), Australasia's largest veterinary research organisation, to facilitate the importation of cannabis for scientific research in companion animals.

CannPal entered into an exclusive master research agreement with Invetus early in the year which includes a provision that allows the Company to store and research its prohibited substances at a secure purpose-built animal health research facility.

The cannabis oils being imported are for the Company's pharmacokinetic and safety studies scheduled to take place in Q1 CY18. The University of Queensland will be providing bio-analytical services for the studies with results anticipated in Q2 CY18.

CannPal's Founder and Managing Director Layton Mills: "Receiving the authorisation to possess and supply cannabis for research from the NSW State Department of Health is a significant milestone for the Company. It will allow us to facilitate the supply of cannabis to our research partners in order to commence the clinical phase of our development plan for CPAT-01. The authorisation is a key step in the Company's plans to import medical cannabis for the purpose of scientific research in companion animals."



About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

To learn more please visit: www.cannpal.com

About Invetus

Invetus is the largest Australasian veterinary contract research organisation (CRO) with sites throughout Australia and New Zealand. Invetus offers a comprehensive range of veterinary research services to generate high-quality information to support the development process. Invetus' customers include animal & human health companies, biotech companies, veterinarians, government and non-government organisations and universities.

To learn more please visit: www.invetus.com

Baden Bowen *Company Secretary, CannPal Animal Therapeutics*

END

For further information, please contact:

CannPal

Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Media enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au



@CannPalAT



facebook.com/CannPal

